Genfit SA (NAS:GNFT)

$ 3.96 -0.13 (-3.24%) Market Cap: 197.45 Mil Enterprise Value: 185.31 Mil PE Ratio: 0 PB Ratio: 2.68 GF Score: 69/100

Half Year 2023 Genfit SA Earnings Call Transcript
Sep 20, 2023

$3.72 (+4.49%)

Earnings
Genfit SA and Ipsen SA Announce Positive Results from Phase III ELATIVE® Trial of Elafibranor in Patients with Primary Biliary Cholangitis Call Transcript
Jun 30, 2023
Full Year 2022 Genfit SA Earnings Call Transcript
Apr 14, 2023

$4 (-1.48%)

Earnings
Genfit SA to Acquire Clinical-Stage Biopharmaceutical Company Versantis AG Call Transcript
Sep 19, 2022
Full Year 2022 Genfit SA Earnings Call Transcript
Apr 08, 2022

$3.95 (+0.77%)

Earnings
Genfit SA Corporate Call Transcript
Dec 17, 2021
Half Year 2021 Genfit SA Earnings Call Transcript
Sep 29, 2021

$3.77 (-1.05%)

Earnings
Genfit SA Updates On Pipeline Transcript
May 11, 2021
Full Year 2020 Genfit SA Earnings Presentation Transcript
Apr 01, 2021
Half Year 2020 Genfit SA Earnings Call (English) Transcript
Sep 30, 2020

$5.27 (-3.30%)

Earnings
Q4 2019 Genfit SA Earnings Call Transcript
Apr 09, 2020

$16.19 (-1.88%)

Earnings

Genfit SA Corporate Call Transcript

Dec 17, 2021 / 12:45PM GMT

Release Date Price: $5.09 (+53.31%)

Transcript

Operator

Good day, and welcome to the Genfit's Corporate Update Conference Call. At this time, I would like to turn the conference over to Ms. Stefanie Magner. Please go ahead, ma'am.

Stefanie Magner

Genfit SA - Chief Compliance Officer & VP of International Legal Affairs

Thank you, and good afternoon, everyone, and thank you for joining us on this conference call, organized to follow-up the 2 press releases we published this morning. The first press release announced the global long-term strategic partnership with Ipsen, beginning with PBC. The second one announced an in-licensing agreement with Genoscience Pharma for an early-stage compound that will be developed as part of our costatic disease franchise. These press releases can be accessed via our website at ir.genfit.com.

During our call, we will be making forward-looking statements as defined under the U.S. Private Securities Litigation Reform Act of 1995 with respect to Genfit, including relating to timing of top line results in the ELATIVE Phase III study, the commercial potential of elafibranor as

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.